相关实验视频
Updated: Jul 24, 2025
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
17.9K
艾滋病毒缓解试验的研究人员对风险的态度和风险减轻在包括治疗中断的试验中的风险
Eunice Akinyi Okumu1, Gail E Henderson2, Carol Golin3,1
1Center for AIDS Research (CFAR), University of North Carolina at Chapel Hill, USA.
Journal of virus eradication
|July 7, 2023
概括
艾滋病毒缓解试验专家预计,在5-10年内将有功能疗法,在10-20年内将有绝育疗法. 他们优先考虑在分析性治疗中断 (ATI) 试验期间减轻对伴侣的艾滋病毒传播风险.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 早期的艾滋病毒缓解试验旨在在没有抗逆转录病毒治疗 (ART) 的情况下消除或持久控制艾滋病毒.
- 分析性治疗中断 (ATI) 在缓解试验中很常见,但增加了参与者和合作伙伴的传播风险.
研究的目的:
- 评估艾滋病毒缓解试验调查人员对实现艾滋病毒治愈的期望.
- 评估人们对艾滋病毒缓解研究的态度,以及ATI期间传播风险减轻策略的可行性,可接受性和有效性.
主要方法:
- 对国际艾滋病毒缓解试验的研究人员和研究小组成员进行了在线问卷调查.
- 受访者对治愈时间表的期望进行了评价,并根据可行性,可接受性和有效性等级对六种艾滋病毒传播风险减轻策略进行了评估.
主要成果:
- 几乎一半的受访者预计在5-10年内获得功能治疗;三分之一的受访者预计在10-20年内获得绝育治疗.
- 与参与者健康风险相比,在ATI期间对合作伙伴的传播风险更令人担忧.
- 要求参与者咨询,合作伙伴PrEP推,直接合作伙伴PrEP提供和性病监测在可行性,可接受性和有效性方面被评为积极的.
结论:
- 艾滋病毒缓解试验的研究人员担心ATI期间的性传播风险.
- 通过通过可行性,可接受性和有效性来评估缓解策略,可以确定最佳方法.
- 需要进一步的研究来比较这些发现与艾滋病毒感染者和试验参与者的观点.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:16Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
01:12Hazard Ratio
165
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
165
01:11Blinding
2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
01:10Retrovirus Life Cycles
46.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.2K